Brca1 Mutation clinical trials

Explore recruiting brca1 mutation clinical trials.

Recruiting brca1 mutation studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Brca1 Mutation trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

Spain, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Brca1 Mutation trials by city

Brca1 Mutation in Toronto Brca1 Mutation in Vancouver Brca1 Mutation in Montreal Brca1 Mutation in Calgary Brca1 Mutation in Edmonton Brca1 Mutation in Ottawa Brca1 Mutation in Winnipeg Brca1 Mutation in Quebec City Brca1 Mutation in Hamilton Brca1 Mutation in Kitchener Brca1 Mutation in London Brca1 Mutation in Halifax Brca1 Mutation in New York Brca1 Mutation in Los Angeles Brca1 Mutation in Chicago Brca1 Mutation in Houston

Brca1 Mutation clinical trials

Recruiting brca1 mutation studies right now

Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

Hormone Replacement Therapy After Risk Reducing Salpingo-oophorectomy

SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells

Cognitive Behavioral Therapy for Fear of Cancer Recurrence in Women With BRCA1/2 Gene

Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors

PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

COsegregation of VARiants in Panel of Genes

Also recruiting in Europe

BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

Brca1 Mutation trials by city

Other conditions